Idun Pharmaceuticals Report issue

For profit Phase 2
Founded: San Diego CA United States (1993)
Status: Acquired by Conatus Pharmaceuticals (2010) → now Histogen (2020)

Organization Overview

First Clinical Trial
2003
NCT00080236
First Marketed Drug
None
First NDA Approval
None
Last Known Activity
2004

Timeline

NOW
  • Now

Mergers & Acquisitions

Historical Acquisition Tree

Active Ingredients

Drugs in Phase 2 Trials (1)

emricasan (2 trials)

Indications

Experimental Indications (Clinical Trials, Phases 1-4)


 

Carcinoma, Hepatocellular (Phase 2)

Cholestasis (Phase 2)

Hepatitis (Phase 2)

Hepatitis A (Phase 2)

Hepatitis C (Phase 2)

Hepatitis C, Chronic (Phase 2)

Overview

  • Highest Phase: Phase 2
  • # of Trials: 2
  • # of Trial APIs: 1